Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Autoimmune diseases in microscopic colitis: A Danish nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Systematic review: gastric microbiota in health and disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Chronic Kidney Disease-Induced Vascular Calcification Impairs Bone Metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.
Original languageEnglish
JournalAlimentary Pharmacology and Therapeutics
Volume37
Issue number12
Pages (from-to)1172-83
Number of pages12
ISSN0269-2813
DOIs
Publication statusPublished - Jun 2013

ID: 39765484